Pharmacological evidence of a role for platelet activating factor as a modulator of vasomotor tone and blood pressure

European Journal of Pharmacology

Volumn 308, Issue 3, 1996, Pages 287-294

  Lopes Martins, Rodrigo ^a   Catelli, Marcelo ^a   Araújo, Cláudia ^a   Estato, Vanessa ^a   Cordeiro, Renato ^a   Tibiriçá, Eduardo ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Arterial pressure; Blood flow; Cyclooxygenase; Endothelium; Glutamate; Noradrenaline; PAF (platelet activating factor); Rabbit; Vasomotor tone

Indexed keywords

APAFANT; GINKGOLIDE B; GLUTAMIC ACID; INDOMETACIN; MEPACRINE; NORADRENALIN; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; BIOSYNTHESIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CAROTID ARTERY OBSTRUCTION; CAROTID SINUS PRESSORECEPTOR REFLEX; CONTROLLED STUDY; DESENSITIZATION; DRUG POTENTIATION; FEEDBACK SYSTEM; FEMALE; HEMODYNAMICS; HYPERTENSION; HYPOTENSION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REGULATORY MECHANISM; VASCULAR RESISTANCE;

EID: 0030601246     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00310-X     Document Type: Article

References (50)

1. Benveniste, J., P.M. Henson and C.J. Cochrane, 1972, Leukocyte-dependent histamine release from rabbit platelets: The role of IgE basophils and a platelet-activating factor, J. Exp. Med. 136, 1356.
2. Bessin, P., J. Bonnet, D. Apffel, C. Soulard, L. Desgroux, I. Pelas and J. Benveniste, 1983, Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs, Eur. J. Pharmacol. 86, 403.
3. Bevan, J.A. and D. Henrion, 1994, Pharmacological implications of the flow-dependence of vascular smooth muscle tone, Annu. Rev. Pharmacol. Toxicol. 34, 173.
4. Bevan, J.A, E.H. Joyce and G.C. Wellman, 1988, Flow-dependent dilation in a resistance artery still occurs after endothelium removal, Circ. Res. 63, 980.
5. Blank, M.L., F. Snyder, L.W. Byers, B. Brooks and E.E. Muirhead, 1979, Antihypertensive activity of an alkyl ether analog of phosphatidylcholine, Biochem. Biophys. Res. Commun. 90, 1194.
6. Braquet, P. and D. Hosford, 1991, Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents, Ethnopharmacology 32, 135.
7. Braquet, P., L. Touqui, T.Y. Shen and B.B. Vargaftig, 1987, Perspectives in platelet-activating factor research, Pharmacol. Rev. 39, 97.
8. Caillard, C.G., S. Mondot, J.L. Zundel and L. Julou, 1982, Hypotensive activity of PAF-acether in rats, Agents Actions 12, 725.
9. Casals-Stenzel, J., G. Muacevic and K.-H. Weber, 1987, Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor, J. Pharmacol. Exp. Ther. 241, 974.
10. Castro-Faria-Neto, H.C., C.V. Araújo, S. Moreira, P.T. Bozza, G. Thomas, J.M. Barbosa-Filho, R.S.B. Cordeiro and E. Tibiriçá, 1995, Yangambin, a new naturally-occurring platelet-activating factor receptor antagonist: in vivo pharmacological studies, Planta Medica 61, 106.
11. Collingridge, G.L. and R.A. Lester, 1989, Excitatory amino acid receptors in the vertebrate central nervous system, Pharmacol. Rev. 40, 143.
12. Cordeiro, R.S.B., M.A. Martins and P.M.R. Silva, 1988, Proinflammatory activity of platelet-activating factor: pharmacological modulation and cellular involvement, Prog. Biochem. Pharmacol. 22, 156.
13. Felix, S.B., G. Baumann, P. Raschke, C. Maus and W.E. Berdel, 1990, Cardiovascular reactions and respiratory events during platelet activating factor-induced shock, Basic Res. Cardiol. 85, 217.
14. Furchgott, R.F., 1983, Role of endothelium in response of vascular smooth muscle, Circ. Res. 53, 557.
15. Gaw, A.J. and J.A. Bevan, 1993, Flow-induced relaxation of the rabbit middle cerebral artery is composed of both endothelium-dependent and -independent components, Stroke 24, 105.
16. Hajra, A.K., 1983, Biosynthesis of O-alkylglycerol ether lipids, in: Ether Lipids. Biochemical and Biomedical Aspects, ed. H.K. Mangold and F. Paltauf (Academic, New York) p. 85.
17. Hanahan, D.J., 1986, Platelet-activating factor: a biologically active phosphoglyceride, Annu. Rev. Biochem. 55, 483.
18. 18-PAF on renal blood flow and systemic blood pressure in the anesthetized rat. Life Sci. 49, 747.
19. Harder, D.R., 1987, Pressure-induced myogenic activation of cat cerebral arteries is dependent on intact endothelium, Circ. Res. 60, 102.
20. Henson, P., P. Barnes and S.P. Banks-Schlegel, 1992, Platelet-activating factor: role in pulmonary injury and dysfunction and blood abnormalities, Am. Rev. Respir. Dis. 145, 726.
21. Imaizumi, T.-A., D.M. Stafforini, Y. Yamada, T.M. McIntyre, S.M. Prescott and G.A. Zimmerman, 1995, Platelet-activating factor: a mediator for clinicians, J. Int. Med. 238, 5.
22. Knowles, R.G., M. Salter, S.L. Brooks and S. Moncada, 1990, Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat, Biochem. Biophys. Res. Commun. 172, 1042.
23. Kobayashi, F., N. Sagawa, Y. Ihara, K. Kitagawa, J. Yano and T. Mori, 1994, Platelet-activating factor-acetylhydrolase activity in maternal and umbilical venous plasma obtained from normotensive and hypertensive pregnancies, Obstet. Gynecol. 84, 360.
24. Koller, A., E.J. Messina, M.S. Wolin and G. Kaley, 1989, Endothelial impairment inhibits prostaglandin and EDRF-mediated arteriolar dilation in vivo, Am. J. Physiol. 257, H1966.
25. Koller, A., D. Sun, A. Huang and G. Kaley, 1994, Corelease of nitric oxide and prostaglandins mediates flow-dependent dilation of rat gracilis muscle arterioles, Am. J. Physiol. 267, H326.
26. Kuo, L.I.H., W.H. Chilian and MJ. Davis, 1991, Interaction of pressure-and flow-induced responses in porcine coronary resistance vessels, Am. J. Physiol. 260, H1706.
27. McGowan, H.M., R. Vandongen, L.D. Kelly and K.J. Hill, 1988, Increased levels of platelet-activating factor (1-O-alkyl-2-acetylglycero-phosphocholine) in blood after reversal of renal clip hypertension in the rat, Clin. Sci. 74, 393.
28. MacManus, L.M., D.J. Hanahan, C.A. Demopoulos and R.N. Pinckard, 1980, Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF) in the rabbit, J. Immunol. 124, 2919.
29. MacManus, L.M., R.N. Pinckard, F.A. Fitzpatrick, R.A. O'Rourke, M.H. Crawford and D.J. Hanahan, 1981, Acetyl glyceryl ether phosphorylcholine: intravascular alterations following intravenous infusion into the baboon, Lab. Invest. 45, 303.
30. Moncada, S., R.M.J. Palmer and E.A. Higgs, 1991, Nitric oxide: physiology, pathophysiology, and pharmacology, Pharmacol. Rev. 43, 109.
31. Novakova, O., J. Drnkova, V. Kubista and F. Novak, 1994, Regulation of phospholipid degradation and biosynthesis in the heart by isoprenaline: effect of mepacrine, Physiol. Res. 43,151.
32. Pohl, V., J. Holtz, R. Busse and E. Bassenge, 1986, Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 8, 37.
33. 2 in vascular smooth-muscle cells, Biochem. J. 299, 197.
34. Rees, D.D. S. Cellek, R.M.J. Palmer and S. Moncada, 1990, Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the effects on vascular tone. An insight into endotoxin shock, Biochem. Biophys. Res, Commun. 173, 541.
35. Robertson, D.A., A. Genovese and R. Levi, 1987, Negative inotropic effect of platelet-activating factor in human myocardium: a pharmacological study, J. Pharmacol. Exp. Ther. 243, 834.
36. Robertson, D.A., D.Y. Wang, C.O. Lee and R. Levi, 1988, Negative inotropic effect of platelet-activating factor: association with a decrease in intracellular sodium activity, J. Pharmacol. Exp. Ther. 245, 124.
37. Rubanyi, G.M. 1988, Endothelium-dependent pressure-induced contraction of isolated canine carotid arteries, Am. J. Physiol. 255, H783.
38. Satoh, K., T.-A. Imaizumi, Y. Kawamura, H. Yoshida, S. Takamatsu and M. Takamatsu, 1989, Increased levels of platelet-activating factor-acetylhydrolase in plasma low density lipoproteins from patients with essential hypertension, Prostaglandins 37, 673.
39. Sawyer, C. H., J. W. Everett and J. D. Green, 1954, The rabbit diencephalon in stereotaxic coordinates, J. Comp. Neurol. 101, 801.
40. Snyder, F., 1990, Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators, Am. J. Physiol. 259, C697.
41. Snyder, F., 1995, Platelet-activating factor: the biosynthetic and catabolic enzymes, Biochem. J. 305, 689.
42. Snyder, F., T.C. Lee and R.L. Wykle, 1985, Ether-linked glycerolipids and their bioactive species: enzymes and metabolic regulation, in: The Enzymes of Biological Membranes, ed. A.N. Martonosi (Plenum, New York) p. 1.
43. Suga, K., T. Kawasaki, M.L. Blank and F. Snyder, 1990, An arachidonoyl (polyenoic)-specific phospholipase A2 activity regulates the synthesis of platelet-activating factor in granulocytic HL-60 cells, J. Biochem. Chem. 265, 12363.
44. Sybertz, E.J., R.W. Watkins, T. Baum, K. Pula and M. Rivelli, 1985, Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphoryl choline in the anesthetized dog, J. Pharmacol. Exp. Ther. 232, 156.
45. B agonist, Br. J. Pharmacol. 115, 1331.
46. Tomlinson, P.R., K. Croft, T. Harris and A.G. Stewart, 1994, Platelet-activating factor biosynthesis in rat vascular smooth muscle cells, J. Vasc. Res. 31, 144.
47. 2 blocks eicosanoid and platelet-activating factor biosynthesis and has topical anti-inflammatory activity, J. Pharmacol. Exp. Ther. 271, 852.
48. Vane, J., 1993, Control of the circulation by endothelial mediators, Int. Arch. Allergy Immunol. 101, 333.
49. Wright, D.T., K.B. Adler, N.J. Akley, L.A. Dailey and M. Friedman, 1994, Ozone stimulates release of platelet activating factor and activates phospholipases in guinea pig tracheal epithelial cells in primary culture, Toxicol. Appl. Pharmacol. 127, 27.
50. Yamanaka, S., M. Katsuyuki, T. Yukimura, M. Okumura and K. Yamamoto, 1992, Putative mechanisms of hypotensive action of platelet-activating factor in dogs, Circ. Res. 70, 893.